Loading...
XNAS
ASND
Market cap14bUSD
Jun 18, Last price  
230.83USD
1D
-0.14%
1Q
4.03%
Jan 2017
1,040.46%
IPO
1,054.15%
Name

Ascendis Pharma A/S

Chart & Performance

D1W1MN
XNAS:ASND chart
P/E
—
P/S
34.39
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.48%
Rev. gr., 5y
93.59%
Revenues
692m
+90.22%
15,583,00020,408,00013,983,0008,118,0004,606,0001,530,00010,581,00013,375,0006,953,0007,778,00051,174,000266,718,000363,641,000691,710,419
Net income
-219m
L-42.07%
1,250,0004,079,000-9,658,000-32,922,000-68,505,000-123,897,000-130,097,000-218,016,000-418,955,000-383,577,000-583,194,000-481,447,000-378,084,000-219,034,140
CFO
52m
P
-652,0006,310,000-18,403,000-43,466,000-60,179,000-95,099,000-138,802,000-175,936,000-271,548,000-417,649,000-495,699,000-467,361,000-306,197,00051,769,836

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
URL
https://ascendispharma.dk/
IPO date
Jan 28, 2015
Employees
797
Domiciled in
DK
Incorporated in
DK

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT